A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors

NCT03184870 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

332

Enrollment

INDUSTRY

Sponsor class

Conditions

Colorectal Cancer
Pancreatic Cancer

Interventions

DRUG: BMS-813160
BIOLOGICAL: Nivolumab
DRUG: Nab-paclitaxel
DRUG: Gemcitabine
DRUG: 5-fluorouracil (5-FU)
DRUG: Leucovorin
DRUG: Irinotecan

Sponsor

Bristol-Myers Squibb